1. Introduction
===============

Primary uterine lymphoma accounts for \<1% of extranodal lymphomas, most of which arise in the cervix.^\[[@R1]\]^ Primary endometrial lymphomas are exceptionally rare. To our knowledge, 20 cases of primary endometrial marginal zone lymphoma (mucosa-associated lymphoid tissue \[MALT\] type) have been reported in the English-language literature.^\[[@R2]--[@R10]\]^ The lack of information on the morphologic spectrum, together with the relatively brief follow-up of prior cases, has hampered classification of these abnormal lymphoid proliferations into the endometrium. We report herein a case of primary endometrial marginal zone lymphoma (MALT type) that showed a good outcome after conservative treatment.

2. Case presentation
====================

A 61-year-old (gravidity 2, parity 2) female was admitted due to postmenopausal vaginal bleeding. She had no significant medical history and no family history of carcinoma. The findings of a chest X-ray and full blood count were normal, as were those of computed tomography (CT) of the abdomen and pelvis. An ultrasound examination revealed a slightly thickened endometrium. The patient subsequently underwent dilatation and curettage (D&C).

Grossly, the specimen was endometrial tissue of 1.5 × 1.0 × 1.0 cm. Microscopically, the endometrium was infiltrated by a monotonous, dense proliferation of small-to-medium-sized atypical lymphoid cells. In some areas, the lymphocytes had scant cytoplasm and slightly irregular nuclei with inconspicuous nucleoli. Scattered transformed blasts were admixed with the small-cell population, and no sign of plasma-cell differentiation was noted (Fig. [1](#F1){ref-type="fig"}A--C).

![Histology of endometrial tissue shows a dense of small-sized to medium-sized atypical lymphocytes with clear cytoplasm and irregular (A, 10×, B, 20×), slightly indented nuclei (C, 40×). Immunohistochemical stains show CD20 (D, 20×) and BCL-2 (E, 20×) positive lymphocytes. The index of Ki67 (F, 20×) was 15%.](medi-98-e15331-g001){#F1}

Immunohistochemistry (IHC) showed that the atypical lymphocytes were positive for CD20 (Fig. [1](#F1){ref-type="fig"}D) and BCL-2 (Fig. [1](#F1){ref-type="fig"}E) and negative for CD5, CD10, BCL-6, cyclinD1, and CD23. The proliferation index, as assessed by Ki-67 IHC, was 15% (Fig. [1](#F1){ref-type="fig"}F). B-cell gene-rearrangement analysis was conducted using the IGH&IGK Kit (Rightone Technology, China) and 3500Dx Genetic Analyzer software (Thermo-Fisher, Waltham, MA), according to the manufacturer\'s protocol. Immunoglobulin heavy-chain locus rearrangements were demonstrated (Fig. [2](#F2){ref-type="fig"}).

![The demonstration of a clonal immunoglobulin heavy-chain locus rearrangement, IGHB.](medi-98-e15331-g002){#F2}

Thus, we established a diagnosis of primary endometrial marginal zone lymphoma (MALT type). Bone marrow biopsy revealed no evidence of lymphoma. According to Ann Arbor criteria, the disease was staged IEA. Therefore, conservative treatment and no further therapy were recommended based on the tumor biology. At the time of writing, the patient had survived with no evidence of cancer for ≥41 months.

3. Discussion
=============

Primary endometrial marginal zone lymphoma (MALT type) is a rare tumor, few cases of which have been reported.^\[[@R2]--[@R10]\]^ Based on prior reports and our case, the most common clinical symptom is postmenopausal or perimenopausal vaginal bleeding/discharge. In the current case, the patient was of typical age and exhibited a typical clinical presentation. The diagnosis was supported by morphologic, IHC, and molecular analyses.

The immunohistochemical profile is useful for diagnosing non-Hodgkin lymphoma (NHL). The most frequently used markers are CD3, CD5, CD10, CD20, CD23, CD43, CD79a, BCL-2, BCL-6, cyclinD1, and ki-67.^\[[@R1]\]^ However, these markers are nonspecific. In our case, IHC suggested an extremely rare malignant B-cell lymphoma of the endometrium. Importantly, the expression of NHL markers should be combined with morphological features. In addition, B-cell gene rearrangements should be investigated.

Most lymphomas in the uterus are secondary to systemic lymphoma, with the cervix being the most frequent site.^\[[@R1]\]^ Primary endometrial marginal zone lymphoma (MALT type) is diagnosed on the basis of the following criteria^\[[@R11]\]^: at the time of initial diagnosis, the lymphoma was primarily confined to the uterine cavity and extensive work-up did not reveal evidence of lymphoma at any other site; no evidence of leukemic phase; and a fairly long interval between the appearance of primary lymphoma and secondary involvement. The patient described herein met these criteria.

The etiology and pathogenesis of extranodal marginal zone lymphoma (EMZL) are unclear, but are associated with chronic infections and autoimmune diseases. Various microorganisms may cause EMZL at mucosal or cutaneous sites. For example, *Helicobacter pylori*, *Chlamydia psittaci*, *Campylobacter jejuni*, and *Borrelia burgdorferi* are reportedly related to gastric mucosa-associated lymphoid tissue or MALT lymphoma, ocular adnexal EMZL lymphoma, immunoproliferative small-intestinal disease, and cutaneous EMZL, respectively.^\[[@R12]\]^ However, there was no evidence of chronic endometritis in the present case.

Primary endometrial marginal zone lymphoma (MALT type) should be distinguished from benign reactive conditions and small-cell lymphomas. Other small-cell lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma can be ruled out by IHC. Negativity for CD5 and CD23 excludes small-cell lymphocytic lymphoma, and negativity for cyclinD1 rules out mantle-cell lymphoma. The absence of follicular-pattern lymphoid cell infiltration and negativity for BCL-6 and CD10 rule out follicular lymphoma.^\[[@R7],[@R8]\]^

As a consequence of the low incidence of primary uterine NHL, there is no approved treatment protocol and no clear association between the outcome and treatment modality has been established. Extranodal marginal zone B-cell lymphomas are regarded as indolent tumors; the 5-year cause-specific survival rate is 94%.^\[[@R13]\]^ Patients with primary endometrial marginal zone lymphoma (MALT type) in prior reports had a good prognosis and none died during the follow-up period.^\[[@R2]--[@R10]\]^ However, most of the patients underwent total hysterectomy,^\[[@R4]--[@R8],[@R10]\]^ and one patient received additional pelvic and paraaortic lymph node radiotherapy.^\[[@R5]\]^ Only 3 patients,^\[[@R2],[@R9]\]^ including ours, were treated with D&C rather than additional surgery or radiotherapy and chemotherapy (Table [1](#T1){ref-type="table"}).
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4. Conclusion
=============

The prognosis of patients with primary endometrial marginal zone lymphoma is related to the stage, location, and biology of the lymphoma. Our patient presented with no symptoms and her blood sample and bone marrow biopsy revealed no evidence of lymphoma, which is in accordance with the generally indolent character of this condition. Thus, conservative treatment was recommended.
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